Literature DB >> 17892411

Anti-apoptotic effect of insulin in the control of cell death and neurologic deficit after acute spinal cord injury in rats.

Xing-Huo Wu1, Shu-Hua Yang, De-Yu Duan, Heng-Hui Cheng, Yu-Ting Bao, Yukun Zhang.   

Abstract

Recent studies confirmed that the new cell survival signal pathway of Insulin-PI3K-Akt exerted cyto-protective actions involving anti-apoptosis. This study was undertaken to investigate the potential neuroprotective effects of insulin in the pathogenesis of spinal cord injury (SCI) and evaluate its therapeutic effects in adult rats. SCI was produced by extradural compression using modified Allen's stall with damage energy of 40 g-cm force. One group of rats was subjected to SCI in combination with the administration of recombinant human insulin dissolved in 50% glucose solution at the dose of 1 IU/kg day, for 7 days. At the same time, another group of rats was subjected to SCI in combination with the administration of an equal volume of sterile saline solution. Functional recovery was evaluated using open-field walking, inclined plane tests, and motor evoked potentials (MEPs) during the first 14 days post-trauma. Levels of protein for B-cell lymphoma/leukemia-2 gene (Bcl-2), Caspase-3, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) were quantified in the injured spinal cord by Western blot analysis. Neuronal apoptosis was detected by TUNEL, and spinal cord blood flow (SCBF) was measured by laser-Doppler flowmetry (LDF). Ultimately, the data established the effectiveness of insulin treatment in improving neurologic recovery, increasing the expression of anti-apoptotic bcl-2 proteins, inhibiting caspase-3 expression decreasing neuronal apoptosis, reducing the expression of proinflammatory cytokines iNOS and COX-2, and ameliorating microcirculation of injured spinal cord after moderate contusive SCI in rats. In sum, this study reported the beneficial effects of insulin in the treatment of SCI, with the suggestion that insulin should be considered as a potential therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17892411     DOI: 10.1089/neu.2006.0228

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  5 in total

1.  Temporal and Regional Expression of Glucose-Dependent Insulinotropic Peptide and Its Receptor in Spinal Cord Injured Rats.

Authors:  Ana Beatriz W Marcos; Stefania Forner; Alessandra C Martini; Eliziane S Patrício; Julia R Clarke; Robson Costa; João Felix-Alves; Vilberto José Vieira; Edinéia Lemos de Andrade; Tânia Longo Mazzuco; João Batista Calixto; Claudia Pinto Figueiredo
Journal:  J Neurotrauma       Date:  2015-12-23       Impact factor: 5.269

2.  Secreted ectodomain of sialic acid-binding Ig-like lectin-9 and monocyte chemoattractant protein-1 promote recovery after rat spinal cord injury by altering macrophage polarity.

Authors:  Kohki Matsubara; Yoshihiro Matsushita; Kiyoshi Sakai; Fumiya Kano; Megumi Kondo; Mariko Noda; Noboru Hashimoto; Shiro Imagama; Naoki Ishiguro; Akio Suzumura; Minoru Ueda; Koichi Furukawa; Akihito Yamamoto
Journal:  J Neurosci       Date:  2015-02-11       Impact factor: 6.167

3.  Therapeutic effect of the combined use of growth hormone releasing peptide-6 and epidermal growth factor in an axonopathy model.

Authors:  Diana García Del Barco; Héctor Pérez-Saad; Valia Rodríguez; Javier Marín; Viviana Falcón; Jorge Martín; Danay Cibrian; Jorge Berlanga
Journal:  Neurotox Res       Date:  2010-02-19       Impact factor: 3.911

4.  Antiapoptotic and neuroprotective effects of mycophenolate mofetil after acute spinal cord injury in young rats.

Authors:  Burcak Bilginer; Mehmet Bulent Onal; Firat Narin; Huseyin Ustun; Kamer Kilinc; Nejat Akalan
Journal:  Childs Nerv Syst       Date:  2009-12       Impact factor: 1.475

5.  Topiramate as a neuroprotective agent in a rat model of spinal cord injury.

Authors:  Firat Narin; Sahin Hanalioglu; Huseyin Ustun; Kamer Kilinc; Burcak Bilginer
Journal:  Neural Regen Res       Date:  2017-12       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.